G2B GATE2BRAIN
LIVE

Serial Number

79304462

Owner

Gate2Brain S.L.

Attorney

Justin R. Young

Filing Date

Dec 30, 2020

Add to watchlist:

No watchlists yet
View on USPTO

G2B GATE2BRAIN Trademark

Serial Number: 79304462 • Registration: 6749116

G2B GATE2BRAIN is a trademark filed by Gate2Brain S.L. on December 30, 2020. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Gate2Brain S.L.

Baldiri Reixac, 4-8, Torre I

Entity Type: 99

Trademark Details

Filing Date

December 30, 2020

Registration Date

June 7, 2022

Published for Opposition

March 22, 2022

Goods & Services

Scientific services, namely, scientific research and testing in the field of drug delivery across biological barriers; research services, namely, pharmaceutical and biomedical research services; research regarding pharmaceutical products, namely, pharmaceutical research services; scientific research in the field of chemistry; biotechnological research; biochemical research and analysis; research and development services in the field of bacteriology; research and development services in the field of vaccines; medical and pharmacological research; scientific research in the fields of biochemistry and biotechnology; food research; stem cell research; development of pharmaceutical products; conducting clinical trials for others relating to pharmaceutical products; development of pharmaceutical preparations and medicines; bacteriological research and consultancy; scientific consultancy relating to research and development in the field of therapeutics; providing information and data services about medical and veterinary research and development; scientific consultancy services; provision of medical research information regarding results of clinical trials relating to pharmaceutical products

Chemical compositions and materials for scientific use, namely, chemicals for use in biomedicine and pharmaceutical sciences; proteins for use in science and industry; proteins for pharmaceutical industry; chemical substances, biochemical substances and natural elements, namely, peptides and proteins for use in the manufacture of pharmaceutical and veterinary products; chemical preparations for scientific use other than for medical or veterinary use

Pharmaceutical products for the treatment of brain related diseases and conditions; medicinal and veterinary products and preparations, namely, preparations for the treatment of central nervous system diseases and conditions; regulatory proteins for medical use for the treatment of central nervous system diseases and conditions; synthetic peptides for pharmaceutical use for the treatment of brain diseases and conditions; vaccines; drug delivery agents in the form of suspension, injectable solution, micelles, micellar solution, solid powder, liophilized powder that facilitate the administering of medicines across biological barriers; pharmaceutical agents acting on metabolism; therapeutic products of bacterial origin, namely, small molecules, proteins and peptides for the treatment of brain diseases; biological preparations for medical use for the treatment of brain diseases and conditions; probiotic bacterial formulations for medical use for the treatment of brain diseases and conditions; stem cells for medical use; nutraceuticals for therapeutic use for the treatment of brain diseases and conditions; pharmaceutical preparations for activating cellular function; chemico-pharmaceutical preparations for the treatment of brain diseases and conditions; dietetic preparations and supplements adapted for medical purposes; nutritional supplements; nutritional supplements for veterinary use; dietary supplements for veterinary use

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Nov 21, 2025 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Nov 7, 2022 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Sep 23, 2022 FICS
FINAL DISPOSITION PROCESSED
Sep 22, 2022 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Sep 7, 2022 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jun 7, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Jun 7, 2022 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 22, 2022 NPUB
PUBLISHED FOR OPPOSITION
Mar 22, 2022 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 2, 2022 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Mar 2, 2022 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 2, 2022 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Feb 14, 2022 PREV
ASSIGNED TO LIE
Feb 14, 2022 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 11, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Feb 11, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 11, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Feb 11, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Feb 11, 2022 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 14, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 14, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 14, 2022 TROA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Nov 17, 2021 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Nov 17, 2021 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Nov 17, 2021 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Nov 17, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Nov 17, 2021 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Nov 17, 2021 COAR
REFUSAL PROCESSED BY IB
Aug 1, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jul 14, 2021 RFCS
REFUSAL PROCESSED BY MPU
Jul 14, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 9, 2021 RFCR
NON-FINAL ACTION WRITTEN
Jul 8, 2021 CNRT
ASSIGNED TO EXAMINER
Jul 4, 2021 DOCK
APPLICATION FILING RECEIPT MAILED
Feb 27, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 23, 2021 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Feb 18, 2021 REPR